Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
October 22, 2014, 10:37:59 PM

Login with username, password and session length


Members
  • Total Members: 23758
  • Latest: mngr5
Stats
  • Total Posts: 643147
  • Total Topics: 48936
  • Online Today: 228
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: The Public Hospital "Carlos III" offers genetic tests for HIV+ Patients  (Read 1061 times)

0 Members and 1 Guest are viewing this topic.

Offline blondbeauty

  • Member
  • Posts: 1,784
http://www.vihpositivo.com/testgenetico230507.htm
MADRID, 22 May. (EUROPE PRESS) the Hospital Carlos III of the Community of Madrid, through its Service of Infectious Diseases, makes of voluntary form genetic test drug to patients with VIH to determine if a antirretroviral drug can cause adverse answers to them. These tests, that they are always made after an informed consent, help to reduce the toxicity problems that can cause the antirretroviral medication and that affects to between a 20% and to 30% of the VIH patients. With all these tests the treatment to the genetic profile of each patient can be adapted, reducing the adverse effects and fitting the doses of medicines with the objective to optimize the treatment. The Hospital Carlos III is pioneering in the accomplishment of a genetic test that determines if a antirretroviral, concretely abacavir, causes hypersensitivity or allergy in the patients. It is very important to detect this data, since it is had to retire immediately the medication to the patient and to indicate it in his clinical history, since a second treatment with this drug can cause very serious consequences for the patient. The activity of the Hospital Carlos III in this matter has taken to the Foundation Ramon Areces to grant a scholarship from investigation to the hospital to identify those genetic markers associate to the appearance of adverse reactions in the patients. The objective to classify this sub-group of patients is to adapt the therapy to its physiological characteristics or their farmacogenético profile. In this work some of the more important adverse effects of the drugs that are used very frequently in the antirretroviral therapy, with the purpose of predicting the risk of development of toxicity study to individualize the therapy. With it the quality of life of the patient would improve and sanitary costs derived from the treatment of the adverse effects would be reduced. The Service of Infectious Diseases of the Hospital Carlos III is specialized in the treatment and the investigation of the VIH. The center gives attendance more than 2,000 patients every year and, at the moment, it makes the test of five new antirretrovirales drugs. This service annually publishes half hundred of scientific articles on the VIH in national and international magazines of forward edge. The equipment directed by doctor Juan González-Lahoz is integrated by doctors, chemistries, phamacists and biologists, who dedicate their work to look for new advances in the fight against AIDS. Tests, volunteers, look for to reduce the toxicity to the antirretrovirales, that affects to between 20% and 30% of the patients.
The only member in these forums approved by WINBA: World International Nail and Beauty Association.
Epstein Barr +; CMV +; Toxoplasmosis +; HIV-1 +.
Counts when starting treatment:
V.L.:80.200 copies. CD4: 25%=503
Started Sustiva-Truvada 14/August/2006
Last V.L.count (Oct 2013): Undetectable
Last CD4 count (OCT 2013): 52%= 933

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.